Vaccines against SARS-COV-2

Julia San Miguel Rodríguez 1, Julita Rodríguez Barbero 1, Angel San Miguel Hernández 2, Angel San Miguel Rodríguez 3, * and María San Miguel Rodríguez 3

1 Hospital Pharmacy Service. Río Hortega University Hospita, Valladolid, Spain.
2 Clinical Analysis Service. Río Hortega University Hospital. Valladolid. International University of La Rioja. Spain.
3 Research Service, Río Hortega University Hospital, Valladolid, Spain.
 
Review Article
GSC Advanced Research and Reviews, 2021, 08(02), 045–057.
Article DOI: 10.30574/gscarr.2021.8.2.0143
Publication history: 
Received on 05 June 2021; revised on 05 August 2021; accepted on 07 August 2021
 
Abstract: 
Vaccines against Covid-19 were developed on the basis of protein S, before it had the mutations identified in these variants. Although research conducted so far is less effective against variants and continues to offer protection against severe forms of Covid-19, further research is ongoing.
WHO is working with every country in the world to help coordinate the key stages of this vaccine manufacturing and development process. In particular, to facilitate equitable access for all countries to vaccines against Covid-19 and that they are safe and effective for the billions of people who need them.
 
Keywords: 
Coronavirus; SARS-COV-2; Mutations; Vaccines
 
Full text article in PDF: 
Share this